Could a tiny dose of IL-2 calm Crohn's flare-ups?

NCT ID NCT04263831

Recruiting now Symptom relief Sponsor: Boston Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times

Summary

This study tests whether a low dose of Interleukin-2 (IL-2) can safely reduce symptoms in people with moderate-to-severe Crohn's disease. About 30 participants aged 12 to 80 will receive the drug to find the best dose that works with the fewest side effects. The goal is to improve quality of life by easing Crohn's symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Locations

Boston Children's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.